Clinical evaluation of the efficacy and safety of Excilor 2-in-1 Wart Treatment in the treatment of verruca vulgaris and verruca plantaris

Medical Brands0 sites66 target enrollmentJuly 27, 2022

Overview

No summary available.

Registry

who.int

Start Date

July 27, 2022

End Date

September 6, 2019

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

Medical Brands

•1\. Sex: female and/or male
•2\. Age: 45 adults 18\-65 years old (inclusive) and 15 children 4\-17 years old (inclusive)
•3\. Subjects with at least one selected wart on the hand or foot not older than 1 year and not previously treated and having a diameter of 2 to 5 mm
•4\. Subjects or parents/legal guardians psychologically able to understand the study\-related information and to give a written informed consent
•5\. Subjects or parents/legal guardians have given freely and expressly their informed consent
•6\. Subjects or parents/legal guardians able to comply with protocol requirements, as defined in the protocol
•7\. Females of childbearing potential should use a medically accepted contraceptive regimen from at least 12 weeks before the beginning of the study till at least 1 month after study completion

•Population:
•1\. Pregnant or nursing subject or planning a pregnancy during the study (females only)
•2\. Subject who had been deprived of her/his freedom by administrative or legal decision or who is under guardianship
•3\. A subject in a social or sanitary establishment
•4\. A subject in an emergency situation
•5\. A subject suspected to be non\-compliant according to the investigator’s judgement
•Associated pathology:
•1\. A subject having clinically significant dermatological pathologies on the tested area, according to the investigator’s judgment
•2\. A subject suffering from a clinically significant illness, stabilized or evolutionary, according to the investigator’s judgement
•3\. Subjects who are suffering from diabetic and/or have a poor blood circulation